← Back
Data updated: Jun 28, 2026
RAFA LABS LTD
Pharma Pharmaceuticals
RAFA LABS LTD is a pharmaceutical company with 2 FDA-approved products.
2018
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
RAFA LABS LTD's Key Drugs
RAFA LABS LTD's core commercial portfolio centers on MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) — its most strategically important drugs approved in the last 15 years.
RAFA LABS LTD's Recent FDA Approvals
New NDA/BLA approvals for RAFA LABS LTD over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
RAFA LABS LTD's Therapeutic Areas
Disease areas where RAFA LABS LTD has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
RAFA LABS LTD Pipeline Snapshot
Active clinical trials for RAFA LABS LTD across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (1)
Company Info
- First Approval
- 2018-07-09
- Latest
- 2024-05-02
- Applications
- 2